In the dose-escalation part of the study, patients with solid tumors and any HER2 status (n = 39), including 26 patients with breast cancer, were enrolled and treated with SYD985 at doses varying from 0.3 to 2.4 mg/kg every three weeks [43]. Here, ERBB2 is linked to breast carcinoma.